CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
CerSci's focus is on alleviating human suffering and rescuing society from the ongoing opioid crisis via a pain drug that does not affect the central nervous system.
North Texas’ growing venture capital community was on full display Thursday at Old Parkland, as an estimated 450 company founders, investors and other community leaders gathered for the sixth annual Venture Dallas conference....
North Texas’ growing venture capital community was on full display Thursday at Old Parkland, as an estimated 450 company founders, investors and other community leaders gathered for the sixth annual Venture Dallas conference....